为全球骨骼肌肉健康解决方案领军者Globus Medical Inc.(纽约证券交易所代码:GMED)周一盘后股价大涨9.55%,主因其2024年第三季度财报超乎市场预期。
财报显示,第三季度Globus Medical调整后每股收益为0.83美元,远高于分析师预期的0.65美元。公司营收达6.257亿美元,同比大增63.1%,也超过华尔街预测的6.0471亿美元。
公司表示,业绩出色主要得益于收购竞争对手NuVasive公司、脊柱产品销量增长强劲,以及使能技术产品及服务销售表现亮眼。数据显示,报告期内Globus Medical在美国和国际市场的销售分别同比增长60.3%和74.8%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.